|Home||Who We Are||Patient Care||Research||News & Events||Programs & Services||Gifts||Contact & Directions|
On October 18, 2012 the radiopharmaceutical substance florbetapir, a component that helps indicate the presence of biomarkers in the brain helpful in diagnosing Alzheimer’s disease, was approved for use in the radioactive dye Amyvid in Europe by the European Medicines Agency.
Florbetapir is the active substance in Amyvid. Florbetapir functions by binding to beta amyloid plaques in the brain, which have been found to be present in neurodegenerative dementias including Alzheimer’s disease. Amyvid is a solution which, when injected, has the ability to show the presence of beta amyloid plaques in the brain using Positron Emmission Tomography, or PET scans.
Amyvid can be used diagnostically to show plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other forms of cognitive impairment. It can also assist in showing a negative scan, which indicates no plaques and is not consistent with a diagnosis of Alzheimer’s disease.